EP
TNGX icon

Essential Partners’s Tango Therapeutics TNGX Stock Holding History

Essential Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125 Hold
4
– – ﹤0.01% 2720
2026
Q1 		$84 Hold
4
– – ﹤0.01% 2740
2025
Q4 		$35 Buy
+4
New +$34 ﹤0.01% 2682

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Essential Partners's TNGX Position: Q2 2026 in Review

Essential Partners held its Tango Therapeutics (TNGX) position steady in Q2 2026 at 4 shares worth $125. The position accounts for ﹤0.01% of the portfolio, ranked #2720.

Essential Partners first reported a position in TNGX in Q4 2025 and has held it in 3 quarters since. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Essential Partners held 4 shares of Tango Therapeutics worth $125 as of Q2 2026.
  • Essential Partners left its Tango Therapeutics share count unchanged in Q2 2026.
  • Tango Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2720 holding.
  • Essential Partners first reported a position in Tango Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.